

Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer

AM Al Murri¹, C Wilson², A Lannigan³, JC Doughty², WJ Angerson¹, CS McArdle¹ and DC McMillan^{*,1}

¹Royal Infirmary, University Department of Surgery, Glasgow, UK; ²Western Infirmary, University Department of Surgery, Glasgow, UK; ³Department of Surgery, Wishaw General Hospital, Lanarkshire, UK

The relationship between the systemic inflammatory response (as evidenced by elevated C-reactive protein and lowered albumin concentrations), clinico-pathologic status and relapse-free, cancer-specific and overall survival was examined in patients with invasive primary operable breast cancer ($n = 300$). The median follow-up of the survivors was 46 months. During this period, 37 patients relapsed and 25 died of their cancer. On multivariate analysis, only tumour size ($P < 0.05$), albumin ($P < 0.01$) and systemic treatment ($P < 0.0001$) were significant independent predictors of relapse-free, cancer-specific and overall survival. Lower serum albumin concentrations ($\leq 43 \text{ g l}^{-1}$) were associated with deprivation ($P < 0.05$), hormonal receptor negative tumours ($P < 0.01$) and significantly poorer 3-year relapse-free (85 vs 93%, $P = 0.001$) cancer-specific (87 vs 97%, $P < 0.0001$) and overall survival (84 vs 94%, $P = 0.001$) rates. The results of the present study suggest that lower preoperative albumin concentrations, but not elevated C-reactive protein concentrations, predict relapse-free, cancer-specific and overall survival, independent of clinico-pathologic status and treatment in patients undergoing potentially curative surgery for primary operable breast cancer.

British Journal of Cancer (2007) 96, 891–895. doi:10.1038/sj.bjc.6603682 www.bjcancer.com

© 2007 Cancer Research UK

Keywords: systemic inflammatory response; C-reactive protein; albumin; primary breast cancer; survival

Breast cancer is the commonest female malignancy and is a major cause of morbidity and mortality in the Western World. For example, in the UK, there are approximately 42 000 new patients each year and almost 13 000 deaths attributable to the disease (CancerStats, 2003).

It is increasingly recognised that variations in outcome in cancer patients are not solely determined by the characteristics of the tumour but also by the host-response factors (Balkwill and Mantovani, 2001; Coussens and Werb, 2002). However, the tumour–host interaction is complex and has yet to be fully understood. It is now accepted that the host systemic inflammatory response can be assessed by examining the changes in the concentrations of acute phase proteins, such as elevated circulating concentrations of C-reactive protein and low concentrations of albumin (Gabay and Kushner, 1999). It is of interest that, either singly or combined, these factors have been shown to be stage independent prognostic factors in patients with a variety of advanced cancers (McMillan *et al*, 2001; Mahmoud and Rivera, 2002; Forrest *et al*, 2003; Crumley *et al*, 2006a, b).

There is also some evidence that the systemic inflammatory response has prognostic value in patients with metastatic breast

cancer. For example, previous studies have reported that the presence of elevated circulating concentrations of C-reactive protein (Williams *et al*, 1990; Albuquerque *et al*, 1995; Zhang and Adachi, 1999; Al Murri *et al*, 2006) and low concentrations of albumin (Heys *et al*, 1998; Al Murri *et al*, 2006) are associated with poorer survival.

However, few studies have examined the prognostic value of the systemic inflammatory response in patients with primary breast cancer (Mortensen and Rudczynski, 1982; Lis *et al*, 2003). Those studies that have, appear to have produced conflicting results with regard to whether C-reactive protein or albumin concentrations have independent prognostic value. For example, Mortensen and Rudczynski (1982) studied almost 300 patients with a follow-up period of 3–48 months post-surgery and reported that the presence of an elevated C-reactive protein concentrations was not an independent prognostic factor. In contrast, Lis *et al* (2003) reported that in almost 200 patients with a follow-up period of 6–84 months, albumin was a stage independent prognostic factor. However, in both these studies, median follow-up was limited and approximately 20% of patients studied had advanced disease.

Therefore, the prognostic value of C-reactive protein and albumin in patients with primary operable breast cancer remains unclear. The aim of the present study was to examine the relationship between clinico-pathologic status, C-reactive protein and albumin concentrations, measured before surgery and cancer-specific survival in patients with invasive primary operable breast cancer.

*Correspondence: Dr DC McMillan;

E-mail: d.c.mcmillan@clinmed.gla.ac.uk

Received 27 September 2006; revised 18 January 2007; accepted 14 February 2007

PATIENTS AND METHODS

Three hundred patients presenting with invasive primary operable breast cancer to two hospitals (Western Infirmary, Glasgow and Wishaw General Hospital, Lanarkshire) in the West of Scotland between June 2001 and July 2003 were prospectively included in the study.

The extent of deprivation was derived from the 1991 census, using the postcode of residence at diagnosis (Carstairs and Morris, 1990, 1991). The results are presented by amalgamating the seven categories into three groups: affluent (categories 1 and 2), intermediate (categories 3–5) and deprived (categories 6 and 7).

Clinico-pathological data including age, deprivation category, histological type, tumour size and grade, lymph node status, oestrogen (ER) and progesterone receptor status. The type of surgery and the use of adjuvant treatment (chemotherapy, hormonal therapy and radiotherapy) was recorded.

Routine preoperative laboratory measurement of C-reactive protein, albumin and white cell count were carried out. At this time, no patients showed clinical evidence of infection or other active chronic inflammatory conditions such as rheumatoid arthritis or crohn's disease. The coefficient of variation for these measurements was less than 10%, as established by routine quality control procedures. The limit of detection of C-reactive protein concentration assay was 6 mg l^{-1} , with the upper limit of normal values being $\leq 10 \text{ mg l}^{-1}$.

The study was approved by the local Research Ethics committees.

Statistics

As appropriate, data are presented as median and range, and comparisons between patient groups were carried out using the χ^2 test or Mann–Whitney *U*-test. Statistical analysis was based on the seven individual deprivation categories. Grouping of the laboratory variables was carried out using standard thresholds

(Goldwasser and Feldman, 1997; O'Gorman *et al*, 2000; McMillan *et al*, 2001; Maltoni *et al*, 2005).

The correlation between C-reactive protein, white cell counts and albumin concentrations was performed using the Spearman's Rank correlation. Relapse-free, cancer-specific and overall survival analyses of the group variables were performed using the Cox proportional hazard model. Deaths up to the end of May 2006 were included in the analysis. Multivariate survival analyses, including all covariates that were significant on univariate analysis, were performed using a stepwise backward procedure to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding *P*-value had to be greater than 0.10. Analysis was performed using SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

The baseline clinico-pathological characteristics of the patients with primary operable breast cancer ($n=300$) are shown in Table 1. Two hundred and thirty-three patients (78%) patients were over 50 years of age; 82 (27%) were in the most deprived categories 6 and 7.

Of the 300 patients, 254 (85%) patients had ductal carcinoma, 122 (41%) had a tumour larger than 2 cm and 130 (43%) had axillary lymph node involvement. The majority of patients had tumour grade II/III (81%) disease. Sixty-two (21%) had ER-negative tumours. Twenty out of 300 (7%) patients had evidence of pre-existing comorbidity, such as liver dysfunction, cardiovascular disease or diabetes mellitus. In one patient, this was severe enough to interfere with planned adjuvant treatment. In all, 288 (96%) patients received adjuvant treatment in the form of endocrine therapy and/or chemotherapy.

The majority had a white cell count, albumin and C-reactive protein concentrations in the normal range (96, 100 and 88%

Table 1 The clinical and pathological characteristics of patients with invasive primary operable breast cancer and survival (relapse-free, cancer-specific and overall survival)

	Patients (n = 300)	Relapse-free survival		Cancer-specific survival		Overall survival	
		Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age ($\leq 50 / > 50$ years)	67/233	2.52 (0.89–7.11)	0.081	1.56 (0.54–4.54)	0.416	2.60 (0.93 – 7.33)	0.070
Deprivation (1–2/3–5/6–7)*	39/179/82	0.93 (0.75–1.14)	0.485	1.01 (0.79–1.31)	0.915	1.10 (0.90–1.36)	0.360
Type (special type/lobular/ductal)	11/35/254	3.09 (0.83–11.55)	0.094	14.97 (0.33–677.82)	0.164	1.23 (0.59–2.60)	0.583
Size ($\leq 20/21–50 / > 50$ mm)	178/117/5	3.29 (1.83–5.94)	<0.0001	3.56 (1.74–7.26)	<0.0001	2.86 (1.62–5.06)	<0.0001
Grade (I/II/III)	56/148/95	2.23 (1.33–3.74)	0.002	2.85 (1.46–5.58)	0.002	1.74 (1.07–2.82)	0.026
Involved lymph node (0/1–3 / > 3)	169/92/38	1.90 (1.25–2.88)	0.003	2.37 (1.44–3.93)	0.001	1.52 (1.01–2.30)	0.046
Hormonal receptor status (ER+ PR+/ER+ PR– or unknown/ER– PR– or unknown)	116/122/62	2.61 (1.66–4.13)	<0.0001	2.76 (1.57–4.85)	<0.0001	1.94 (1.26–2.97)	0.002
White cell count (10^9 l^{-1})**	7.0 (3.4–17.4)	0.97 (0.83–1.15)	0.755	0.94 (0.76–1.16)	0.559	1.04 (0.89–1.21)	0.619
White cell count ($< 8.5/8.5–11 / > 11 \times 10^9 \text{ l}^{-1}$)	230/53/13	0.81 (0.41–1.60)	0.547	1.07 (0.52–2.21)	0.857	1.36 (0.81–2.29)	0.247
Albumin concentration (g l^{-1})**	44 (35–52)	0.88 (0.78–0.99)	0.035	0.82 (0.71–0.94)	0.006	0.88 (0.78–0.98)	0.026
Albumin concentration ($> 43 / \leq 43 \text{ g l}^{-1}$)	155/114	3.39 (1.61–7.12)	0.001	5.01 (1.85–13.57)	0.002	3.23 (1.58–6.59)	0.001
C-reactive protein concentration (mg l^{-1})**	≤ 6 ($\leq 6–66$)	0.96 (0.88–1.04)	0.293	0.97 (0.89–1.06)	0.518	0.97 (0.90–1.04)	0.391
C-reactive protein ($\leq 10 / > 10 \text{ mg l}^{-1}$)	265/35	0.40 (0.10–1.68)	0.211	0.62 (0.15–2.65)	0.522	0.60 (0.19–1.95)	0.395
Loco-regional treatment (mastectomy or conservation surgery+radiotherapy/mastectomy+radiotherapy)	221/79	3.70 (1.94–7.06)	<0.0001	5.51 (2.43–12.48)	<0.0001	2.40 (1.27–4.51)	0.007
Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none)	150/86/52/9	2.03 (1.43–2.88)	<0.0001	2.59 (1.67–4.01)	<0.0001	1.93 (1.37–2.73)	<0.001

Abbreviations: CI, confidence interval; ER, oestrogen receptor; PR, progesterone receptor. *Individual deprivation categories were used in the statistical analysis and **median (range).

respectively) before surgery. White cell count was correlated with C-reactive protein ($r_s = 0.13$, $P = 0.023$) but not albumin concentration ($r_s = 0.03$, $P = 0.587$). Albumin was correlated with C-reactive protein concentration ($r_s = -0.19$, $P = 0.002$).

The minimum follow-up was 35 months; the median follow-up of the survivors was 46 months. During this period, 37 patients relapsed and 25 died of their cancer; a further 14 patients died of intercurrent disease.

On univariate survival analysis, age ($P < 0.10$), tumour type ($P < 0.10$), tumour size ($P < 0.0001$), grade ($P < 0.01$), lymph node involvement ($P < 0.01$), hormone receptor status ($P < 0.0001$), albumin ($P \leq 0.001$), loco-regional treatment ($P < 0.0001$) and systemic treatment ($P < 0.0001$) were significantly associated with relapse-free survival. On multivariate analysis of these significant covariates, age (HR 5.02, 95%CI 1.49–16.93, $P = 0.009$), tumour size (HR 2.34, 95%CI 1.18–4.62, $P = 0.015$), albumin (HR 3.65, 95%CI 1.71–7.78, $P = 0.001$), loco-regional treatment (HR 2.56, 95%CI 1.17–5.59, $P = 0.019$) and systemic treatment (HR 2.26, 95%CI 1.54–3.32, $P < 0.0001$) were significant independent predictors of relapse-free survival.

On univariate survival analysis, tumour size ($P < 0.0001$), grade ($P < 0.01$), lymph node involvement ($P \leq 0.001$), hormone receptor status ($P < 0.0001$), albumin ($P < 0.01$), loco-regional treatment ($P < 0.0001$) and systemic treatment ($P < 0.0001$) were significantly associated with cancer-specific survival. On multivariate analysis of these significant covariates, tumour size (HR 2.53, 95%CI 1.15–5.55, $P = 0.021$), albumin (HR 4.44, 95%CI 1.60–12.28, $P = 0.004$), loco-regional treatment (HR 3.55, 95%CI 1.30–9.67, $P = 0.013$) and systemic treatment (HR 2.67, 95%CI 1.56–4.57, $P < 0.0001$) were significant independent predictors of cancer-specific survival.

On univariate survival analysis, age ($P < 0.10$), tumour size ($P < 0.0001$), grade ($P < 0.05$), lymph node involvement ($P < 0.05$), hormone receptor status ($P < 0.01$), albumin ($P \leq 0.001$), loco-regional treatment ($P < 0.01$) and systemic treatment ($P < 0.001$) were significantly associated with overall survival. On multivariate analysis of these significant covariates, age (HR 4.19, 95%CI 1.26–13.91, $P = 0.019$), albumin (HR 3.33, 95%CI 1.60–6.90, $P = 0.001$), tumour size (HR 2.48, 95%CI 1.36–4.55, $P = 0.003$) and systemic

treatment (HR 2.10, 95%CI 1.45–3.05, $P < 0.0001$) were significant independent predictors of overall survival.

Patients were then grouped according to albumin concentrations ($>43/\leq 43 \text{ g l}^{-1}$) as shown in Table 2. A lower serum albumin concentration ($\leq 43 \text{ g l}^{-1}$) was associated with deprivation ($P < 0.05$), hormonal receptor negative tumours ($P < 0.01$) and significantly poorer 3-year relapse-free (85 vs 93%, $P = 0.001$), cancer-specific (87 vs 97%, $P < 0.0001$) and overall survival (84 vs 94%, $P = 0.001$) rates.

DISCUSSION

Predicting recurrence and survival following potentially curative surgical resection for primary operable breast cancer is conventionally based on standard clinico-pathological criteria such as age, tumour size and grade, nodal status and hormonal receptor status. However, it was of interest that other host-related factors, such as the systemic inflammatory response, have previously been shown to be associated with poor survival following a potentially curative resection for a variety of cancers including gastro-oesophageal, pancreatic, colorectal and urinary bladder cancers (McMillan et al, 2003; Hilmy et al, 2005; Jamieson et al, 2005; Crumley et al, 2006a,b).

In the present study, albumin but not C-reactive protein was a significant, stage independent, predictor of survival in patients with primary operable breast cancer. The relationship between albumin concentrations and outcome are therefore consistent with those previously reported in patients with advanced breast cancer (Heys et al, 1998; Al Murri et al, 2006).

Previous studies have shown that elevated C-reactive protein concentrations have prognostic value in patients with a variety of primary operable tumours (Ikeda et al, 2003; McMillan et al, 2003; Hilmy et al, 2005; Jamieson et al, 2005) and also in patients with advanced breast cancer (Williams et al, 1990; Albuquerque et al, 1995; Zhang and Adachi, 1999; Al Murri et al, 2006). It was therefore unexpected that C-reactive protein, either as a continuous or categorical variable, was not a significant prognostic factor in the present study.

Table 2 The clinico-pathological characteristics of patients with invasive primary operable breast cancer according to albumin concentrations

	Albumin $> 43 \text{ g l}^{-1}$ (n = 155)	Albumin $\leq 43 \text{ g l}^{-1}$ (n = 114)	P-value
Age ($\leq 50 / > 50$ years)	35/120	26/88	0.965
Deprivation (1–2/3–5/6–7)*	26/90/39	13/68/33	0.011
Type (special type/lobular/ductal)	8/17/130	3/15/96	0.524
Size ($\leq 20/21–50 / > 50$ mm)	96/57/2	62/49/3	0.384
Grade (I/II/III)	31/72/52	18/65/30	0.201
Involved lymph node (0/1–3/ > 3)	93/47/15	60/35/18	0.269
Hormonal receptor status (ER+ PR+/ER+ PR– or unknown/ER– PR– or unknown)	80/47/28	35/54/25	0.002
White cell count (10^9 l^{-1})**	6.8 (3.6–13.9)	7.0 (3.4–17.4)	0.920
White cell count ($< 8.5/8.5–11 / > 11 \times 10^9 \text{ l}^{-1}$)	127/18/8	83/27/3	0.281
C-reactive protein (mg l^{-1})**	< 6 ($< 6–57$)	< 6 ($< 6–66$)	0.138
C-reactive protein ($\leq 10 / > 10 \text{ mg l}^{-1}$)	136/19	102/12	0.660
Loco-regional treatment (mastectomy or conservation surgery+radiotherapy/mastectomy+radiotherapy)	120/35	78/36	0.098
Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none)	74/52/25/3	64/25/21/4	0.185
3 years relapse-free survival rate***	93 (2)	85 (3)	0.001
3 years cancer-specific survival rate***	97 (1)	87 (3)	< 0.0001
3 years overall survival rate***	94 (2)	84 (3)	0.001

Abbreviations: ER, oestrogen receptor; PR, progesterone receptor. *Individual deprivation categories were used in the statistical analysis, **median (range) and ***3-year survival rate (SE).

The basis of this observation is not clear. However, an elevated C-reactive protein concentration ($>10 \text{ mg l}^{-1}$) was seen in only 12% of patients, a proportion lower than previously seen in both primary operable disease (approximately 20–40%) and in advanced cancer (approximately 40–80%). This may, in part, reflect the relatively small number of events relating to relapse-free survival, cancer-specific and overall survival in the present study.

It was of interest that, of the two acute-phase proteins examined in the present study, albumin, generally considered to be a relatively insensitive measure of the systemic inflammatory response, had independent prognostic value, even with values within the normal range. It has been previously shown that small reductions in albumin concentrations are associated with certain comorbid conditions such as liver dysfunction, cardiovascular disease or diabetes mellitus and poorer survival in the general population (Goldwasser and Feldman, 1997). In the present study, only 7% of patients had such comorbidity (only one patient had planned adjuvant treatment altered) and therefore this would suggest that there may be an interaction between breast cancer and albumin concentrations, which might impact on the survival of these patients.

The mechanism by which a low serum albumin might impact on relapse-free, cancer-specific and overall survival is not clear. It may reflect the biological functions of circulating albumin including binding and transporting of hormones and growth factors, inhibition of platelet function and thrombosis (Margaron and Soni, 1998). Furthermore, albumin in the breast cancer cell cytosol may inhibit tumour growth (Soreide *et al*, 1991) and tumour cell proliferation by modulating the activities of autocrine growth regulatory factors (Laursen *et al*, 1990).

REFERENCES

- Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. *Br J Cancer* **94**: 227–230
- Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, Blamey RW, Robertson JF (1995) Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. *Eur J Surg Oncol* **21**: 504–509
- Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* **357**: 539–545
- CancerStats (2003) Cancer incidence and mortality reports. <http://info.cancerresearchuk.org/cancerstats/reports>
- Carstairs V, Morris R (1990) Deprivation and health in Scotland. *Health Bull (Edinburgh)* **48**: 162–175
- Carstairs V, Morris R (1991) *Deprivation and Health in Scotland*. Aberdeen: University Press
- Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature* **420**: 860–867
- Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC (2006a) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. *Br J Cancer* **94**: 1568–1571
- Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006b) Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. *Br J Cancer* **94**: 637–641
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer* **89**: 1028–1030
- Gabay C, Kushner I (1999) Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* **340**: 448–454
- Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. *J Clin Epidemiol* **50**: 693–703
- Heys SD, Ogston KN, Simpson WG, Walker LG, Hutcheon AW, Sarkar TK, Eremin O (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. *Int J Oncol* **13**: 589–594
- Hilmy M, Bartlett JM, Underwood MA, McMillan DC (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. *Br J Cancer* **92**: 625–627
- Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. *Ann Surg* **238**: 197–202
- Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. *Br J Cancer* **92**: 21–23
- Laursen I, Briand P, Lykkesfeldt AE (1990) Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. *Anticancer Res* **10**: 343–352
- Lis CG, Grutsch JF, Vashi PG, Lammerfeld CA (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? *J Parenter Enteral Nutr* **27**: 10–15
- Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. *Curr Oncol Rep* **4**: 250–255
- Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study by the steering committee of the European Association for Palliative Care. *J Clin Oncol* **23**: 6240–6248
- Margaron MP, Soni N (1998) Serum albumin: touchstone or totem? *Anaesthesia* **53**: 789–803
- McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. *Br J Surg* **90**: 215–219

- McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. *Nutr Cancer* **41**: 64–69
- Mortensen RF, Rudczynski AB (1982) Prognostic significance of serum CRP levels and lymphoid cell infiltrates in human breast cancer. *Oncology* **39**: 129–133
- O’Gorman P, McMillan DC, McArdle CS (2000) Factors predicting survival of advanced gastrointestinal cancer patients with weight loss. *Nutr Cancer* **37**: 36–40
- Soreide JA, Lea OA, Kvinnsland S (1991) Cytosol albumin content in operable breast cancer. Correlation to steroid hormone receptors, other prognostic factors and prognosis. *Acta Oncol* **30**: 797–802
- Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW (1990) An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. *Br J Cancer* **61**: 126–132
- Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. *Anticancer Res* **19**: 1427–1432